Galleri Cancer Blood Test Wins Mixed but Favorable FDA Panel Vote
FDA panel endorsed GRAIL’s Galleri as an add-on cancer blood test. Approval is not final. Coverage, labeling, and whether it saves lives remain open.
FDA panel endorsed GRAIL’s Galleri as an add-on cancer blood test. Approval is not final. Coverage, labeling, and whether it saves lives remain open.
FDA posted Galleri briefing papers with no leftover lab-test questions. Panel meets Sept. 23; approval odds remain in focus.
GRAIL’s Galleri cancer blood test will be reviewed by FDA experts as the company seeks full approval for early cancer detection.
At ASCO 2026, Grail’s Galleri multi-cancer blood test showed promise but missed its main goal in the large NHS trial. Experts say it’s not ready for broad population screening yet.
TD Cowen upgrades Grail to Buy from Hold with $65 target after 60% selloff. Analyst sees attractive entry in multi-cancer detection despite NHS study miss.
GRAIL shares plunged 38% after hours despite promising NHS-Galleri trial results. The blood test missed its main goal but cut late-stage cancers and boosted early detection 4x.